KRAS and non-small cell lung carcinoma: Even if the population who may benefit from EGFR inhibitors (such as patients who are positive for an EGFR mutation and negative for a K-ras mutation) is very small, the response rate of over 80% is encouraging, and has never before been achieved in advanced NSCLC.